This two-site immunoradiometric assay for human parathyrin-related protein 1-86 (PTHRP1 -86) in plasma uses a mouse monoclonal antibody to PTHRP1 -34 coupled to cellulose particles for immunoextraction of N-terminal immunoreactivity, and a rabbit antiserum to PTHRP37-67 that is indirectlylabeled with 1251-labeledPTHRP37-67 for quantifying the bound analyte. The detection limit of the assay is 0.23 pmol/L, corresponding to 0.4 pg (0.04 and which arise by alternative splicing of . The amino terminus and midregion of PTHRP are highly conserved between species (13), and the protein is relatively rich in lysine and arginine residues, which may be possible sites of proteolytic cleavage. Little is known regarding the posttranslational processing or metabolism of PTHRP, and the major circulating forms are not yet identified.
reflecting increased bone resorption and reduced urinary excretion of calcium; increased urinary phosphate excretion; and increased excretion of nephrogenous cAMP (5). Because of overwhelming evidence that PTH itself is rarely responsible for HHM (3, 6), peptides with PTH-like activity were implicated as possiblemediators of HHM. In 1987, the search for the factor(s) involved led to the isolation and identification of PTHRP from two cancer cell lines and a tumor associatedwith hypercalcemia (7) (8) (9) . Cloning of cDNA for PTHRP predicted a protein of 141 amino acids having significant homology of its amino terminus to that of PTH (10). Subsequent studies have predicted three native forms of the protein, of 139, 141, and 173 amino acids, which differ only at the carboxyl terminus and which arise by alternative splicing of . The amino terminus and midregion of PTHRP are highly conserved between species (13), and the protein is relatively rich in lysine and arginine residues, which may be possible sites of proteolytic cleavage. Little is known regarding the posttranslational processing or metabolism of PTHRP, and the major circulating forms are not yet identified.
Sequence homology with PTH is greatest at the amino terminus, where eight of the first 13 amino acids for each molecule are identical (10). The PTH-like bioactivity of PTHRP, like that of PTH, is contained within the first 34 amino acids, and evidence suggests that this activity is expressed via P'I'H receptors (14). Although some differences in the relative potencies of PTH and PTHRP have been reported, in vitro studies show that P'F}{RP is at least as potent as PTH in stimulating cAMP by osteogenic sarcoma cells and renal membranes (15), promoting resorption of bone (16), and inhibiting phosphate transport (17) . In vivo studies also provide convincing evidence that the biochemical features of HHM may be explained by excessproduction of P'FHRP (18, 19) .
Although PTHRP in biological fluids (e.g., cell culture fluid, milk, and tissue extracts) has been assayed by in vitro bioassays involving stimulation of cAMP production by osteosarcoma cell lines and renal membranes, these methods generally lack the sensitivity required to assay circulating PTHRP. Bioactive P'FHRP has been assayed in plasma by highly sensitive cytochemical bioassays, but these methods are complex and impractical for clinical studies (20) . A further disadvantage of the bioassays is their potential for cross-reaction with
PTH.
To date, immunoassays described for plasma PTHRP include a direct radioimmunoassay for PTHRP1-34 (21), an RIA for PTHRP1-34 in affinity extracts of serum (22), including one somatostatinoma and two pancreatic islet tumors), breast (two), renal cortex (three), prostate (two), esophagus (two), bladder (one), ovary (one), malignant pheochromocytoma (one), and liver (one). Three patients had an unidentified abdominal mass, and in five, the site of the primary tumor was uncertain. The majority of these patients were studied as they presented in local hospital practice. Samples from patients with rare neuroendocrine malignancies (somatostatinoma, pancreatic islet cell tumors, and pheochromocytoma) were referred from hospitals elsewhere in the U.K. Tumor histology was not available in all cases and is therefore not described. Most patients had advanced malignancy; metastatic disease was clinically apparent in 20, although this may be an underestimate because a systematic search for metastases was not feasible in all patients. Seven patients had received intravenous bisphosphonates to inhibit bone resorption and, although serum calcium concentrations had fallen at the time of sampling, corrected calcium remained increased in six and became normal in one. The serum calcium concentrations were corrected for the effect of low serum albumin concentrations: corrected calcium (mmol/L) = total calcium (mmol/L) + 0.02 [40 -albumin (gIL)].
Methods
Preparation ofPTHRP37-67 immunogen.
We coupled PTHRP37-67 to BSA by using heterobifunctional (1 mol/L, pH 7.0), we desalted the reaction solution as described above. The molar ratio of thiol groups coupled to BSA, determined by using 4,4'-dithiodipyridine, was 25:1. We then coupled PTHRP37-67 and BSA overnight at 4#{176}C at a molar ratio of approximately 25:1. We desalted the conjugate by dialysis against phosphate-buffered saline (PBS), pH 7.4, and stored it at -20 #{176}C.
Production and characterization
of antisera to PTHRP37-67.
We immunized five rabbits with 150 pg of PTHRP37-67-BSA conjugate emulsified in Freund's complete adjuvant. We gave subsequent boosts of 25 g of conjugate in Freund's incomplete adjuvant at four-to six-week intervals, and bled the rabbits seven days later. Titer was determined by incubation with 1251.. labeled PTHRP37-67 (15 000 counts/mn), in Buffer A. The specificity of the selected antiserum was examined by RIA by incubating PTHRP37-67, PTHRP38-64 amide, PTH1-84, PTH.RP1-86, or dilutions of culture fluid from the BEN lung cancer cell line overnight at 4#{176}C with 100 L each of 1251-labeled P'FHRP37-67 (15 000 counts/mn) and 3000-fold-diluted anti-PTHRP37-67, in a total volume of 0.5 mL. We used Sac-Cel to separate antibody-bound and free fractions. We iodinated PTHRP37-67 (2 tg) in the presence of ['I]NaJ (1.0 mCi) and Chloramine T (10 pig) and purified the product by passing it through a C18 Sep-Pak cartridge as previously described (24) . The incorporation of radioiodine was between 85% and 95%; the specific activity of the tracer ranged from 400 to 450 Ci/g. The shelf life of the tracer was four weeks at 4#{176}C. 
86.
The following reagents and assay conditions were optimized in the development of the IRMA. The dilution of the anti-PTHRP1-34 cellulose suspension selected corresponded to 0.5-1.0 mg/tube and gave maximum binding of PTHRP1-86. In the case of rabbit anti-P'FHRP37-67, 50 j.zL of a 200-fold dilution gave maximum binding and economical use of this antiserum. Addition of increasing amounts of 1251-labeled PTHRP37-67 increased both specific and nonspecific binding of tracer. Because the signal-to-noise ratio remained relatively constant for different amounts of the label, we selected 100 000-120 000 counts/mn per tube arbitrarily. The incubation conditions selected gave optimal specific binding in the assay, and also allowed the assay to be completed within one and one-half working days. A sample volume of 200 pL gave satisfactory assay sensitivity. Preliminary studies showed the response was linearly related to sample volume (up to 500 p.L), suggesting that assay sensitivity may be further improved by increasing the sample volume.
Sample collection and handling.
Blood was collected from patients and volunteers either by syringe or into evacuated tubes with use of lithium heparin as anticoagulant. Ideally, plasma was separated from cells within 30 mm of collection and stored at -20 #{176}C until assay.
Statistics.
We used a two-way analysis of variance for statistical analysis.
Results

Characterization
of antiserum to PTHRP37-67.
All five rabbits produced antisera that bound 'I-labeled PTHRP37-67 in titers ranging from <1:5000 to 1:50 000 after two booster immunizations. Antisera from three of the five rabbits cross-reacted with PTHRP in human milk, culture medium from the BEN lung cancer cell line, and human keratinocytes. One of these antisera (no. 3592) was compatible with MAb 1D5 in a two-site assay. In an RIA for PTHRP37-67, the detection limit corresponding to 95% of specificbinding was 30 pg/tube (17 pmol/L). P'FHRP1-86 and PTHRP38-64 amide crossreacted in the assay but produced dilution curves that were nonparallel to that of the standard, whereas culture medium from the BEN cell line and keratmnocytes and human milk yielded dilution curves that approximately paralleled that of PTHRP37-67. We found no cross-reaction with P'FH1-84 (up to 100 ng/tube, 20.2 nmol/L).
Characterization of MAb 1D5 to PTHRPI-34. 
MAb
Linearity.
The relationship between PTHRP1-86 concentration and sample volume is shown in Figure 3 . The five specimens studied were from patients with cancerassociated hypercalcemia. Nonlinearity was apparent at the highest PTHRP1-86 concentrations, particularly at those >10-15 pmol/L, and indicated that such speci- Fig. 1 . IRMA standardcurve for PTHRP1-86
The insert shows thestandard curve for PTHRP1-56 at ow concentrations.
Vertical bars represent ± 2 SD 9 (SD 2.5), 14.8 (SD 3.7; P <0.01), and 11.4 (SD 4.1 5 (SD 8.3 ), 31.8 (SD 10.5; P <0.01), and 23.8 (SD 9.6; P <0.01) pmoIJL. These combined data suggest that exogenous PTHRP1-86 is degraded in blood and donor serum at ambient temperature, -50% being lost after 4 h. As many as three cycles of freeze-thawing had no significant effect on the immunoreactivity of standard FFHRP1-86 added to donor serum.
Plasma
PTHRP1-86 concentrations.
Although we
were unable to demonstrate differences in PTHRP1-86 measured in plasma or serum from normal subjects, Indirect labeling of the polyclonal antiserum makes unnecessary affinity purification of the antiserum, with its associated losses, so that the available antiserum can be used as economically as possible. This assay design provides excellent analytical performance, with a low detection limit and good precision. For PTH1-84, Blind et al. (29) reported comparable performance with that of conventional two-site assays involving a single incubation step with antibodies labeled directly, with or without a radioisotope (30, 31 pmol/L, but in only 57% were the concentrations clearly above the absolute upper reference limit of normal (11 pmol/L). In the present study, P'FHRP1-86 concentrations were detectable and increased (>0.23 pmol/L) in 35 of 37(95%) patients with cancer-associated hypercalcemia. Differences in the prevalence of above-normal PTHRP concentrations between studies based on either affinity extraction or two-site IRMA are probably due, in part, to differences in patient selection, given the absence of generally agreed-upon criteria for classifying cancer-associated hypercalcemia.
The absolute P'FHRP1-86 concentrations reported here are similar to previous estimates of PTH-like bioactivity in HHM, as measured by cytochemical bioassay (20) . The positive correlation between PTHRP and calcium concentrations was also reported in an earlier study (22) . In our study, PTHRP1-86 was detectable in only one of 16 patients with cancer who had normal calcium concentrations in plasma. Overall, these results provide convincing evidence that PTHRP may have a humoral role in the majority of patients with malignancy-associated hypercalcemia with suppressed PTH concentrations, although they do not exclude the possibility that other tumor factors may be involved.
Many of the patients with above-normal PTHRP1-86 concentrations had tumors commonly associated with HHM (3), e.g., lung (11), esophagus (2), renal cortex (3), liver (1), ovary (1), whereas others had rare tumors that have only recently been associated with HHM and increased secretion of PTHRP, e.g., pancreatic islet cell tumors (two), (32) and pheochromocytoma (one) (33). The finding of increased PTHRP1-86 concentrations in a patient with breast cancer suggests that hunioral mechanisms involving PTHRP may have a role in malignancies in which hypercalcemia is usually attributed to local osteolytic mechanisms. Further work is required to examine PTHRP concentrations systematically in a range of malignancies in which the histological and metastatic status is more rigorously assessedthan was possible in the present study.
The role of PTHRP in primary hyperparathyroidism remains to be resolved. Although there is good evidence of increased mRNA for P'FHRP in parathyroid adenomas (34), and positive staining for PTHRP in adenomas by immunohistochemistry (35) , immunoassay of circulating PTHRP concentrations has not provided convincing evidence of increased PTHRP secretion in this condition (22,23). In 23 patients with chronic renal failure, PTHRP1-86 concentrations were slightly increased in five. Others have reported detectable concentrations in chronic renal failure, using a two-site IRMA of PTHRP1-74; they also found uniformly increased concentrations when using an RIA of PTHRP1O9-138 (23). It is not clear whether these observations reflect impaired clearance or increased production of PTHRP and its fragments.
The relationship between immuno-and bioactivity of circulating PTHRP also needs further investigation. As with most proteins of similar molecular size, circulating fragments may retain immunological activity, even when bioactivity, which requires an intact amino-terminal region (e.g., PTHRP1-30) (36), is lost. Nevertheless, the excellent clinical discrimination found in hypercalcemic states in the present study and the demonstrated cross-reaction of native forms, but not of the aminoterminal subfragments of PTHRP, suggeststhat immunoactive PTHRP1-86 concentrations are related to those molecular speciesin plasma with biological activity.
